ProQR Therapeutics N.V. Ordinary Shares (PRQR) Stock Price

PRQRStock

$1.31−53.21%52W

Market Cap$184.87M

P/E—

PEG Ratio—

Div yield—

Beta0.23

PRQR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-44.08%

Price vs S&P 500 (4W)-28.24%

VGM Score51.23

Book Value / Share (Quarterly)$0.63

P/TBV (Annual)5.88x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)50.45%

Cash Flow / Share (Quarterly)$-0.40

Price vs S&P 500 (YTD)-47.08%

Net Profit Margin (TTM)-228.18%

EPS (TTM)$-0.44

10-Day Avg Trading Volume0.92M

EPS Excl Extra (TTM)$-0.44

Revenue Growth (5Y)11.58%

EPS (Annual)$-0.45

ROI (Annual)-64.56%

Net Profit Margin (5Y Avg)-923.85%

Cash / Share (Quarterly)$0.93

Revenue Growth QoQ (YoY)120.35%

ROA (Last FY)-37.41%

Revenue Growth TTM (YoY)7.49%

EBITD / Share (TTM)$-0.42

ROE (5Y Avg)-67.66%

Operating Margin (TTM)-232.60%

Cash Flow / Share (Annual)$-0.56

P/B Ratio2.07x

P/B Ratio (Quarterly)2.77x

Net Income / Employee (Annual)$-253,238

EV / Revenue (TTM)3.40x

Net Interest Coverage (TTM)-13.09x

ROA (TTM)-35.80%

EPS Incl Extra (Annual)$-0.45

Current Ratio (Annual)3.09x

Quick Ratio (Quarterly)3.41x

3-Month Avg Trading Volume1.00M

52-Week Price Return-53.21%

Revenue / Employee (TTM)$110,567

Tangible BV / Share (Quarterly)$2.42

P/S Ratio (Annual)10.06x

Asset Turnover (Annual)0.14x

52-Week High$3.48

Operating Margin (5Y Avg)-899.36%

EPS Excl Extra (Annual)$-0.45

CapEx CAGR (5Y)2.09%

Tangible BV CAGR (5Y)10.74%

26-Week Price Return-34.17%

Quick Ratio (Annual)3.01x

13-Week Price Return-22.94%

Total Debt / Equity (Annual)0.32x

Current Ratio (Quarterly)3.49x

Enterprise Value$70.36M

Revenue / Share Growth (5Y)-3.84%

Asset Turnover (TTM)0.16x

Book Value / Share Growth (5Y)-15.36%

Revenue / Employee (Annual)$98,107

Pretax Margin (Annual)-257.94%

Cash / Share (Annual)$0.96

3-Month Return Std Dev60.71%

Net Income / Employee (TTM)$-252,340

ROE (Last FY)-85.44%

Net Interest Coverage (Annual)-21.33x

EPS Basic Excl Extra (Annual)$-0.45

P/FCF (TTM)13.26x

Receivables Turnover (TTM)36.70x

Total Debt / Equity (Quarterly)0.19x

EPS Incl Extra (TTM)$-0.44

Receivables Turnover (Annual)0.17x

ROI (TTM)-58.58%

P/S Ratio (TTM)8.93x

Pretax Margin (5Y Avg)-921.60%

Revenue / Share (Annual)$0.17

Tangible BV / Share (Annual)$2.42

Price vs S&P 500 (52W)-68.75%

Year-to-Date Return-35.15%

5-Day Price Return-19.14%

EPS Normalized (Annual)$-0.45

ROA (5Y Avg)-28.35%

Net Profit Margin (Annual)-258.05%

Month-to-Date Return-21.08%

Cash Flow / Share (TTM)$-0.48

EBITD / Share (Annual)$-0.44

Operating Margin (Annual)-265.77%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-49.32%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.44

P/TBV (Quarterly)5.88x

P/B Ratio (Annual)3.83x

Pretax Margin (TTM)-228.04%

Book Value / Share (Annual)$0.51

Price vs S&P 500 (13W)-25.63%

Beta0.23x

P/FCF (Annual)8.15x

Revenue / Share (TTM)$0.19

ROE (TTM)-75.23%

52-Week Low$1.46

vGradeC

gGradeB

mGradeD

vgmGradeC

PRQR Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.21	-$0.10	+49.54%(+$0.10)
Q1 2026	May 12, 2026	-$0.20	-$0.17	+14.63%(+$0.03)
Q4 2025	Mar 12, 2026	-$0.13	-$0.10	+21.16%(+$0.02)
Q3 2025	Nov 6, 2025	-$0.19	-$0.14	+29.08%(+$0.06)
Q2 2025	Aug 7, 2025	-$0.10	-$0.16	-49.85%(-$0.06)

PRQR Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.27

4.31

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PRQRProQR Therapeutics N.V. Ordinary Shares	C	B	D	8.9x	7.5%	—	—	$1.31
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About ProQR Therapeutics N.V. Ordinary Shares

ProQR Therapeutics NV develops RNA-based therapeutics for severe genetic rare diseases, including cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The company's entire research and development effort is dedicated to discovering and advancing RNA therapeutics.

PRQR Next Earnings Report

Report dateNov 5, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$0.12

Revenue estimate$5.54M

Also reporting on Nov 5, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

PRQR Insider Transactions

BuyJul 31, 2026
DE BOER DANIEL ANTON
Chief Executive Officer
Shares: 200,000Value: $353,960

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for July 2026

Companies in Related Industries

PLXProtalix BioTherapeutics, Inc. Common StockBiological Products
ALECAlector, Inc. Common StockBiological Products
NAGENiagen Bioscience, Inc. Common StockPharmaceutical Preparations
CGENCompugen LtdBiological Products
LTBRLightbridge Corp.Industrial Chemicals
IVVDInvivyd, Inc. Common StockBiological Products
STROSutro Biopharma, Inc.Biological Products
ACOGAlpha Cognition Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

Price Range (33 wk)

Low$1.31

High$2.43